Skip to content

COMBINE (Acamprosate/Naltrexone)

COMBINE: Effect of Combined Pharmacotherapies and Behavioral Interventions

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00006206
Enrollment
1375
Registered
2000-09-12
Start date
1997-08-31
Completion date
2006-05-31
Last updated
2010-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholism

Brief summary

Combine is a multicenter, randomized clinical trial that will evaluate combinations of three interventions for treating alcohol dependence. The goal is to determine whether improvement in treatment outcomes can be achieved by various combinations of drug and behavioral interventions. Two of the interventions will consist of pharmacological treatment with naltrexone (Revia) or acamprosate (Campral). The third intervention is a multicomponent behavioral therapy including such components as motivational enhancement therapy, cognitive behavioral therapy, and referral to self-help groups, including AA. All three interventions will include a component supporting compliance to medications and reduction in drinking.

Interventions

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
Lipha Pharmaceuticals
CollaboratorINDUSTRY
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

The following inclusion criteria are to be met: 1. Male and female outpatients \> 18 years of age. 2. Participants will have a current DSM-IV diagnosis of alcohol dependence. 3. Participants will have signed a witnessed informed consent. 4. Participants must have been drinking a minimum of \> 14 drinks (females) or \> 21 drinks (males) on average per week over a consecutive 30-day period in the 90-day period prior to initiation of abstinence, and have two or more days of heavy drinking (defined as 4 drinks for females and 5 drinks for males) in the 90-day period prior to initiation of abstinence. 5. Participants must have had a minimum of 4 consecutive days (96 hours) of abstinence and have a CIWA \< 8 prior to randomization. 6. Participants can be abstinent for a maximum of 21 days prior to randomization. 7. Participants will have no more than 21 consecutive days of planned absence during the 16 week active treatment period. 8. Participants who are able to identify at least one locator person to assist in tracking the participant for follow-up assessment. 9. Participants who are able to speak and understand English.

Exclusion criteria

The following

Design outcomes

Primary

MeasureTime frame
Percent days abstinent
Time to relapse to heavy drinking

Secondary

MeasureTime frame
measures of drinking outcomes ((duration of abstinence, measures of frequency and intensity, et al.)
psychological assessments
quality of life
measures of adverse experiences

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 11, 2026